Lead Product(s) : OBI-902
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Clears IND for OBI-902 Phase 1/2 Trop-2 ADC Study by OBI Pharma
Details : OBI-902 is the first ADC utilizing OBI’s proprietary GlycOBI® ADC enabling technology. It is being evaluated for advanced solid tumors.
Product Name : OBI-902
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
April 30, 2025
Lead Product(s) : OBI-902
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OBI-992
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Biosion
Deal Size : Inapplicable
Deal Type : Inapplicable
Biosion's Partner OBI Pharma Announces FDA Clearance for OBI-992 Phase 1/2 Study
Details : OBI-992 is a novel antibody drug conjugate (ADC) cancer therapy targeting TROP2. It is being evaluated for the treatment of non-small cell lung cancer, small cell lung cancer & gastric cancer.
Product Name : OBI-992
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
August 01, 2024
Lead Product(s) : OBI-992
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Biosion
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Silmitasertib
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Senhwa Biosciences Gets FDA Study May Proceed Letter for Silmitasertib in Young Patients
Details : CX-4945 (silmitasertib) is a first-in-class small molecule drug that acts as a CK2 inhibitor. It is being evaluated for the treatment of relapsed refractory solid tumors in children & young adults.
Product Name : CX-4945
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 08, 2024
Lead Product(s) : Silmitasertib
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ACE2016
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Acepodia Announces FDA Clearance of IND Application for ACE2016 Anti-EGFR Cell Therapy
Details : ACE2016 is an allogeneic gamma delta 2 T cell therapy. It's IND application is cleared after preclinical studies for the treatment of EGFR-expressing malignancies in patients with solid tumors.
Product Name : ACE2016
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 02, 2024
Lead Product(s) : ACE2016
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OBI-992
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
OBI Pharma Announces FDA Clearance for Phase 1/2 Study of OBI-992
Details : OBI-992 is a TROP2-targeted antibody-drug conjugate delivering a topoisomerase I inhibitor, evaluated for advanced solid tumors including lung and gastric cancers.
Product Name : OBI-992
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
March 01, 2024
Lead Product(s) : OBI-992
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ACE2016
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ACE2016 is an off-the-shelf, gamma delta-2 T cell therapy designed to recognize and engage solid tumors expressing EGFR by ACC technology unlocking multiple receptor signaling causing tumor cell apoptosis.
Product Name : ACE2016
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 27, 2023
Lead Product(s) : ACE2016
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pidnarulex,Talazoparib
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Peter MacCallum Cancer Centre
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pidnarulex synthetically derived small molecule in combination with Talazoparib (PARP inhibitor), potential therapy in patients with metastatic castration-resistant prostate cancer.
Product Name : CX-5461
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 22, 2021
Lead Product(s) : Pidnarulex,Talazoparib
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Peter MacCallum Cancer Centre
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ACE1702
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Acepodia received clearance of its Investigational IND application from U.S FDA to start Phase 1 clinical study of its natural killer cell therapy ACE1702 in patients with HER2-expressing solid tumors.
Product Name : ACE1702
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 01, 2020
Lead Product(s) : ACE1702
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable